220463-42-3

Upstream product

• 220461-59-6 1-[4-(4H,10H-pyrazolo[5,1-c][1,4]benzodiazepine-5-carbonyl) phenyl]-ethanone 
• 5815-08-7 tert-Butoxybis(dimethylamino)methane 

Downstream Products

• 220461-61-0 [4-(2-methyl-2H-pyrazol-3-yl)phenyl](4H,10H-pyrazolo[5,1-c][1,4]-benzodiazepin-5-yl)methanone 
• 220461-60-9 [4-(1-methyl-1H-pyrazol-3-yl)phenyl](4H,10H-pyrazolo[5,1c][1,4]-benzodiazepin-5-yl)methanone 

Relevant academic research and scientific papers

Vasopressin agonist formulation and process

This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having the general structure: and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.